Status:
UNKNOWN
Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Collaborating Sponsors:
Society of Critical Care Medicine
Conditions:
Critical Illness
Corona Virus Infection
Eligibility:
All Genders
14+ years
Brief Summary
The cytokine storms mediated by over production of proinflammatory cytokines have been observed in a large population of critically ill patients infected with COVID-19. Patients diagnosed with cytokin...
Detailed Description
This study will provide further insight whether anti-IL6 alone provide same efficacy and clinical outcome with reasonable side effects profile compared to anti-IL6 + corticosteroid and might serve as ...
Eligibility Criteria
Inclusion
- Adult Critically ill patients
- COVID-19 PCR positive
- Presence of clinical and radiological signs of progressive disease, and laboratory evidence indicative of risk for cytokine storm complications.
- Received anti-IL6 or corticosteroids as part of COVID-19 treatment
Exclusion
- Non COVID-19 related admissions
- Repeated Admission to ICUs/Hospital
- Patient did not receive anti-IL6 or corticosteroids
Key Trial Info
Start Date :
July 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 22 2021
Estimated Enrollment :
860 Patients enrolled
Trial Details
Trial ID
NCT04486521
Start Date
July 22 2020
End Date
July 22 2021
Last Update
March 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Faisal Specialist Hospital and Research Center
Riyadh, Saudi Arabia